Hepato-Gastroenterology Department, Claude Huriez Hospital, University of Lille, Lille, France.
Department of Digestive Diagnostic and Interventional Radiology, Claude Huriez Hospital, University of Lille, Lille, France.
Aliment Pharmacol Ther. 2020 May;51(9):889-898. doi: 10.1111/apt.15681. Epub 2020 Mar 27.
The notion of Crohn's disease (CD) as a chronic, progressive and disabling condition has led to the development of new indexes: the Lémann Index measuring cumulative bowel damage and the Inflammatory Bowel Disease (IBD) Disability Index, assessing functional disability.
To measure the Lémann Index and the IBD Disability Index in a large prospective cohort of CD patients and to assess the correlation between these two indexes.
We performed a prospective study in a tertiary referral centre including all consecutive CD outpatients. We assessed the Lémann Index and the IBD Disability Index questionnaire in all patients.
One hundred and thirty CD patients were consecutively included. The mean Lémann Index (±SD) was 11.9 ± 14.1 and ranged from 0 to 72.5 points. Factors associated with a high bowel damage score were: disease duration, anal location, previous intestinal resection, clinical and biological disease activity, exposure to immunosuppressants, and exposure to anti-TNF (P < 0.005). Among patients exposed to anti-TNF, the Lémann Index was lower in those who were exposed in the first 2 years of their disease (P = 0.015). The mean IBD Disability Index was 28.8 ± 6.3 and ranged from 0 to 71 points. The factors associated with high disability score were: female gender, anal location, extra digestive manifestations, clinical and biological disease activity and exposure to anti-TNF (P < 0.005). No correlation was observed between the Lémann Index and IBD Disability Index (P = 0.15).
This is the first study to prospectively evaluate the Lémann Index and the IBD Disability Index in a large cohort of CD patients in a tertiary centre. Early introduction of anti-TNF treatment was associated with lower bowel damage scores, and no correlation was observed between the Lémann Index and the IBD Disability Index. Further dedicated prospective studies are necessary to confirm these results.
克罗恩病(CD)是一种慢性、进行性和致残性疾病,这导致了新指数的发展:累积肠道损伤的勒曼指数和评估功能障碍的炎症性肠病(IBD)残疾指数。
在大型 CD 患者前瞻性队列中测量勒曼指数和 IBD 残疾指数,并评估这两个指数之间的相关性。
我们在一家三级转诊中心进行了一项前瞻性研究,纳入了所有连续的 CD 门诊患者。我们对所有患者进行了勒曼指数和 IBD 残疾指数问卷评估。
连续纳入了 130 名 CD 患者。平均勒曼指数(±SD)为 11.9±14.1,范围为 0 至 72.5 分。与高肠道损伤评分相关的因素包括:疾病持续时间、肛门位置、既往肠道切除术、临床和生物学疾病活动、免疫抑制剂暴露和抗 TNF 暴露(P<0.005)。在暴露于抗 TNF 的患者中,疾病的前 2 年暴露于抗 TNF 的患者勒曼指数较低(P=0.015)。平均 IBD 残疾指数为 28.8±6.3,范围为 0 至 71 分。与高残疾评分相关的因素包括:女性、肛门位置、消化道外表现、临床和生物学疾病活动以及抗 TNF 暴露(P<0.005)。勒曼指数与 IBD 残疾指数之间无相关性(P=0.15)。
这是第一项在三级中心前瞻性评估大型 CD 患者勒曼指数和 IBD 残疾指数的研究。早期引入抗 TNF 治疗与较低的肠道损伤评分相关,勒曼指数与 IBD 残疾指数之间无相关性。需要进一步的专门前瞻性研究来证实这些结果。